I-Hyalgan iyisisombululo esivumayo esiqukethe i-sodium hyaluronate ehlanzekile (Hyalectin) e-saline yomzimba. I-Hyalgan ingenye yama-hyaluronates asetshenziselwa i- viscosupplementation - ukwelashwa okubandakanya ukujova i-gel-like substance (hyaluronate) ibe yingxenye yokwengeza izindawo ezibucayi ze- synovial fluid . I-viscosupplement ejojelwe isiza ukuxubha okuhlangene futhi inikeze ukugcoba ukunciphisa ukungqubuzana okwenzeka ngokunyakaza.
Nge- osteoarthritis , i-synovial fluid ilahlekelwa izakhiwo zayo zokugcoba futhi umgomo we-viscosupplementation ukubuyisela lezo zakhiwo.
Izinkomba ze-Hyalgan
UHyalgan yamukelwa yi-US Food and Drug Administration (FDA) ngoMeyi 28, 1997, njengendlela yokwelapha ye- knee osteoarthritis . Kuthathwa njengokwelashwa, hhayi umuthi. I-hyaluronate ye-sodium e-Hyalgan isuswa kuma-como we-rooster. I-Hyalgan iboniswa iziguli ezinobuhlungu obuhlobene ne-knee osteoarthritis ehlulekile ukufeza ukukhululeka ngezokwelapha okungezona izidakamizwa ezingavamile kanye nama-analgesics alula, njenge- acetaminophen .
Ukuphathwa kwe-Hyalgan
I-Hyalgan ingumjovo we- intra-articular ngokuvamile onikezwe kanye ngesonto, ngesonto elilodwa ngaphandle, okwenziwe ama-injection angu-5. Ezinye iziguli zingase zithole umphumela ophumelelayo emva kwemijikelezo engu-3 yamasonto onke, ngokusekelwe emiphumeleni yocwaningo yeziguli ezithola ama-injection amathathu bese zilandelwa izinsuku ezingu-60.
Ukuqapha nokuxwayiswa
Kunezinyathelo eziningi zokuqapha nezixwayiso ezihlobene nemigudu ye-Hyalgan intra-articular:
- Ukuphepha nokusebenza kwe-Hyalgan ngamalungu ngaphandle kwamadolo akuzange kufundwe.
- Uma isiguli sinamaprotheni ezinamaprotheni ezinyoni, izimpaphe noma amaqanda, umjovo kufanele wenziwe ngokuqapha.
- Kungase kube nobuhlungu noma ukuvuvukala ngomjovo ozokwehlisa. Kunconywa, njengokungathi yonke injection ye-intra-articular, ukuthi iziguli azihlanganyeli emisebenzini eqinile noma enesisindo sokusebenza kwamahora angu-48 ngemva kokujola.
- Ukuphepha nokusebenza kwe-Hyalgan injection akuzange kusungulwe kwabesifazane abakhulelwe, noma kwabesifazane abakhulelwe. Ukusetshenziswa kwalo akukafundwanga ezinganeni.
Imiphumela emibi nezenzakalo ezimbi
Imiphumela emibi evamile ehlotshaniswa ne-Hyalgan injection ihlanganisa izinkinga zomzimba, ukulimala kwendawo yomjovo, ukuvuvukala kwamadolo noma ukuqhuma, ukukhwabanisa kwesikhumba sendawo, ukuhlakulela, nokukhanda ikhanda. Imiphumela emibi kakhulu yilezi zindlela zokungenwa kwesayithi eziwela phansi ngemuva kwezinsuku ezimbalwa, ikakhulukazi ngokuphumula nokusetshenziswa kweqhwa. Ukunakwa kufanele kukhokhelwe izimpawu eziphikelela futhi zingase zibonise okuthile okunzima nakakhulu, njengokungenwa yisifo noma ukuguqulwa kwesistimu. Izenzakalo ezinzima ezinjalo zibhekwa njengezingavamile.
Okubalulekile
I-Hyalgan yayiyi-viscosupplement yokuqala evunywe yi-FDA ngo-Meyi 1997. Amanye ama-viscosupplements avunyelwe i-FDA, kanye nosuku avunyelwe ngalo, afaka:
- I-Synvisc 08/08/1997
- I-Supartz 01/24/2001
- I-Orthovisc 02/05/2004
- Euflexxa 12/03/2004
Umthombo:
I-Hyalgan (i-Sodium Hyaluronate). Ukubeka imininingwane. I-Fidia Pharma USA. Meyi ebuyekeziwe ngo-2014.